Bristol Licenses Dragonfly’s IL-12 Program To Boost Immunotherapies
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.
You may also be interested in...
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.